Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study
暂无分享,去创建一个
M. Harrow | T. Jobe | R. Faull | M. Harrow | T. H. Jobe | R. N. Faull | M. Harrow
[1] S. Dursun,et al. Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients , 2012, Therapeutic advances in psychopharmacology.
[2] P. McGorry,et al. Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. , 2013, JAMA psychiatry.
[3] M. Harrow,et al. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? , 1994, Schizophrenia bulletin.
[4] M. Bleuler. The schizophrenic disorders: Long-term patient and family studies , 1978 .
[5] J. Endicott,et al. A diagnostic interview: the schedule for affective disorders and schizophrenia. , 1978, Archives of general psychiatry.
[6] V. Goghari,et al. A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders , 2012, Psychological Medicine.
[7] D. Quinlan,et al. Disordered Thinking and Schizophrenic Psychopathology , 1985 .
[8] I. Glick,et al. A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.
[9] Ronald Pierson,et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. , 2011, Archives of general psychiatry.
[10] P. Hutton,et al. Antipsychotics: is it time to introduce patient choice? , 2012, British Journal of Psychiatry.
[11] M. Harrow,et al. Psychotic unipolar depression at follow-up: factors related to psychosis in the affective disorders. , 1994, The American journal of psychiatry.
[12] M. Harrow,et al. Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? , 2013, Schizophrenia bulletin.
[13] S. Silverstein,et al. A scientific agenda for the concept of recovery as it applies to schizophrenia. , 2008, Clinical psychology review.
[14] A. Jablensky,et al. What Did the WHO Studies Really Find? , 2007, Schizophrenia bulletin.
[15] D. Wiersma,et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. , 2013, JAMA psychiatry.
[16] L. Ciompi,et al. Soteria Berne: an innovative milieu therapeutic approach to acute schizophrenia based on the concept of affect-logic. , 2004, World psychiatry : official journal of the World Psychiatric Association.
[17] D. Healy,et al. Neuroleptic discontinuation syndromes , 1998, Journal of psychopharmacology.
[18] D. Penn,et al. Psychosocial treatments for schizophrenia. , 2013, Annual review of clinical psychology.
[19] R. Rosenheck,et al. Compliance with medication regimens for mental and physical disorders. , 1998, Psychiatric services.
[20] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[21] J. Moncrieff. The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment , 2007 .
[22] Robin M. Murray,et al. Schizophrenia: From developmental deviance to dopamine dysregulation , 2008, European Neuropsychopharmacology.
[23] Dan J Stein,et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia , 2008, Schizophrenia Research.
[24] M. Harrow,et al. Factors Involved in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications: A 15-Year Multifollow-Up Study , 2007, The Journal of nervous and mental disease.
[25] G. Vaillant. A 10-year followup of remitting schizophrenics. , 1978, Schizophrenia bulletin.
[26] A. B. Hollingshead,et al. Social Class and Mental Illness , 1964 .
[27] J. Strauss,et al. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. , 1987, The American journal of psychiatry.
[28] Kenneth S. Kendler,et al. The Dopamine Hypothesis of Schizophrenia: An Historical and Philosophical Analysis , 2011 .
[29] L. Ciompi,et al. Psychosocial treatment, antipsychotic postponement, and low‐dose medication strategies in first‐episode psychosis: A review of the literature , 2009 .
[30] L. Grossman,et al. Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. , 2005, Schizophrenia bulletin.
[31] T. McGlashan,et al. Sustained remission in drug-free schizophrenic patients. , 1987, The American journal of psychiatry.
[32] Michael F. Green,et al. Neurocognitive and social cognitive correlates of formal thought disorder in schizophrenia patients , 2006, Schizophrenia Research.
[33] J. Moncrieff. A critique of the dopamine hypothesis of schizophrenia and psychosis. , 2009, Harvard review of psychiatry.
[34] H. Meltzer,et al. Outcome in manic disorders. A naturalistic follow-up study. , 1990, Archives of general psychiatry.
[35] A. St-Hilaire,et al. Life events and high-trait reactivity together predict psychotic symptom increases in schizophrenia. , 2009, Schizophrenia bulletin.
[36] Philip Seeman,et al. The Creation of Psychopharmacology , 2002, Nature Medicine.
[37] J. Veijola,et al. A systematic review and meta-analysis of recovery in schizophrenia. , 2013, Schizophrenia bulletin.
[38] John M. Davis,et al. Maintenance treatment with antipsychotic drugs for schizophrenia. , 2012, The Cochrane database of systematic reviews.
[39] R. Murray,et al. The Myth of Schizophrenia as a Progressive Brain Disease , 2012, Schizophrenia bulletin.
[40] D. Weinberger,et al. Remission in schizophrenia: proposed criteria and rationale for consensus. , 2005, The American journal of psychiatry.
[41] Julie Kreyenbuhl,et al. Practice guideline for the treatment of patients with schizophrenia , 1997 .
[42] R Kikinis,et al. Superior temporal gyrus volume abnormalities and thought disorder in left-handed schizophrenic men. , 1999, The American journal of psychiatry.
[43] P. McHugh,et al. Long-term follow-up of patients hospitalized for schizophrenia, 1913 to 1940. , 1997, The Journal of nervous and mental disease.
[44] M. Harrow,et al. Schizophrenia Course, Long-Term Outcome, Recovery, and Prognosis , 2010 .
[45] B. Jones,et al. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. , 1980, The American journal of psychiatry.
[46] Scott J. Russo,et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity , 2012, Nature Neuroscience.
[47] Johannes Schwarz,et al. Psychosis pathways converge via D2High dopamine receptors , 2006, Synapse.
[48] F. Basset,et al. Anatomy of an Epidemic – Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America , 2012 .
[49] D. Jeste,et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. , 1995, Archives of general psychiatry.
[50] D. Charney,et al. Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. , 2004, The American journal of psychiatry.
[51] J. Aaltonen,et al. The Comprehensive Open-Dialogue Approach in Western Lapland: II. Long-term stability of acute psychosis outcomes in advanced community care , 2011 .
[52] P. Cohen,et al. The clinician's illusion. , 1984, Archives of general psychiatry.
[53] R. Baldessarini,et al. International consensus study of antipsychotic dosing. , 2010, The American journal of psychiatry.
[54] R. G. Hunt,et al. Social Class and Mental Illness , 1959 .
[55] M. Harrow,et al. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study , 2012, Psychological Medicine.
[56] M. Harrow,et al. How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. , 2010, Schizophrenia bulletin.
[57] J. Racoosin,et al. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. , 2004, Diabetes care.
[58] C. Waternaux,et al. One hundred years of schizophrenia: A meta-analysis of the outcome literature , 1993, Schizophrenia Research.
[59] E. Zigler,et al. A developmental approach to adult psychopathology , 1986 .
[60] Nancy H. Covell,et al. Mental health system funding of cognitive enhancement interventions for schizophrenia: summary and update of the New York Office of Mental Health expert panel and stakeholder meeting. , 2013, Psychiatric rehabilitation journal.
[61] K. Kaplan,et al. Thought Disorder in Schizophrenia: Working Memory and Impaired Context , 2004, The Journal of nervous and mental disease.
[62] T. McGlashan,et al. Risk factors for psychosis: impaired social and role functioning. , 2012, Schizophrenia bulletin.
[63] D. Wiersma,et al. Guided Discontinuation Versus Maintenance Treatment in Remitted First-Episode Psychosis: Relapse Rates and Functional Outcome , 2007 .
[64] Nathan Clark. Consensus development conference on antipsychotic drugs and obesity and diabetes. , 2004, The Journal of clinical psychiatry.
[65] P. Seeman,et al. Is schizophrenia a dopamine supersensitivity psychotic reaction? , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[66] Fredrick C. Redlich,et al. Social class and mental illness: Community study. , 1958 .
[67] North American Association for the Study of Obesity , 1991, International journal of obesity.
[68] D. Kelly,et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements , 2012 .